Continuous venovenous hemodiafiltration in the treatment of newborns with an inborn metabolic disease: a single center experience
- PMID: 31014046
- PMCID: PMC7080361
- DOI: 10.3906/sag-1811-8
Continuous venovenous hemodiafiltration in the treatment of newborns with an inborn metabolic disease: a single center experience
Abstract
Background/aim: Most inborn metabolic diseases are diagnosed during the neonatal period. The accumulation of toxic metabolites may cause acute metabolic crisis with long-term neurological dysfunction and death. Renal replacement therapy (RRT) modalities allow the efficient removal of toxic metabolites. In this study, we reviewed our experience with continuous venovenous hemodiafiltration (CVVHDF) as RRT for newborns with an inborn metabolic disease.
Materials and methods: Patients diagnosed with an inborn metabolic disease and who received CVVHDF treatment at our neonatal intensive care unit between January 2014 and December 2017 were included in this study. Their demographic and clinical data were collected, and the efficacy and safety of CVVHDF was evaluated.
Results: A total of nine continuous RRT (CRRT) sessions as CVVHDF were performed in eight newborns with a diagnosis of urea cycle defect (n = 5), maple syrup urine disease (n = 2), or methylmalonic acidemia (n = 1). The mean age at admission was 10 ± 8.6 days (range: 3–28 days). The mean plasma levels of ammonium were 1120 ± 512.6 mg/dL and 227.5 ± 141.6 mg/dL before and at the end of the treatment, respectively. Plasma levels of leucine were 2053.5 ± 1282 μmol/L and 473.5 ± 7.8 μmol/L before and at the end of the treatment, respectively. The CVVHDF duration was 32.3 ± 11.1 h (median: 37 h; range: 16–44 h), and the mean length of hospitalization was 14.6 ± 12.9 days. The mean duration of CVVHDF was 32.3 ± 11.1 h (range: 16–44 h). Circuit clotting was the most common observed complication (37.5%) and the survival rate was 50%. Among surviving patients, two developed severe and two developed mild mental and motor retardation.
Conclusion: CVVHDF is a CRRT modality that can be used to treat newborns with an inborn metabolic disease. Early diagnosis, commencement of specific medical therapy, diet, and extracorporeal support, if needed, are likely to result in improved short and long- term outcomes.
Keywords: Inborn metabolic diseases; renal replacement therapy; continuous venovenous hemodiafiltration; newborn; survival.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Conflict of interest statement
None declared
Similar articles
-
Short-term results of continuous venovenous haemodiafiltration versus peritoneal dialysis in 40 neonates with inborn errors of metabolism.Eur J Pediatr. 2019 Jun;178(6):829-836. doi: 10.1007/s00431-019-03361-4. Epub 2019 Mar 20. Eur J Pediatr. 2019. PMID: 30895385
-
Characteristics of continuous venovenous hemodiafiltration in the acute treatment of inherited metabolic disorders.Pediatr Nephrol. 2022 Jun;37(6):1387-1397. doi: 10.1007/s00467-021-05329-9. Epub 2021 Oct 25. Pediatr Nephrol. 2022. PMID: 34693482 Free PMC article.
-
Continuous Venovenous Hemodiafiltration in the Treatment of Maple Syrup Urine Disease.Blood Purif. 2016;42(1):27-32. doi: 10.1159/000443783. Epub 2016 Mar 22. Blood Purif. 2016. PMID: 26998605
-
Experience with continuous venovenous hemodiafiltration in four newborns: A case series and review of the literature.Hemodial Int. 2015 Oct;19(4):E59-62. doi: 10.1111/hdi.12234. Epub 2014 Oct 20. Hemodial Int. 2015. PMID: 25330394 Review.
-
[Continuous venovenous hemodiafiltration in critically ill patients with acute renal failure].Ugeskr Laeger. 2000 May 15;162(20):2868-71. Ugeskr Laeger. 2000. PMID: 10860424 Review. Danish.
Cited by
-
[Application of continuous renal replacement therapy in the treatment of neonates with inherited metabolic diseases].Zhongguo Dang Dai Er Ke Za Zhi. 2021 May;23(5):488-493. doi: 10.7499/j.issn.1008-8830.2101073. Zhongguo Dang Dai Er Ke Za Zhi. 2021. PMID: 34020739 Free PMC article. Chinese.
-
Inborn errors of metabolism in neonates and pediatrics on varying dialysis modalities: a systematic review and meta-analysis.Pediatr Nephrol. 2025 Jul;40(7):2177-2188. doi: 10.1007/s00467-024-06547-7. Epub 2024 Nov 11. Pediatr Nephrol. 2025. PMID: 39523291 Free PMC article.
References
-
- Arbeiter AK Kranz B Wingen AM Wingen AM Bonzel KE Continuous venovenous haemodialysis (CVVHD) and continuous peritoneal dialysis (CPD) in the acute management of 21 children with inborn errors of metabolism. Nephrology Dialysis Transplantation. 2010;25:1257. - PubMed
-
- Surtees RA Matthews EE Leonard JV Neurologic outcome of propionic acidemia. Pediatric Neurology. 1992;8:333. - PubMed
-
- Msall M Batshaw ML Suss R Brusilow SW Neurologic outcome in children with inborn errors of urea synthesis: Outcome of urea cycle enzymopathies. New England Journal of Medicine. 1984;310:1500. - PubMed
-
- Hilliges C Awiszus D Wendel U. Intellectual performance of children with maple syrup urine disease. European Journal of Pediatrics. 1993;152:144. - PubMed
-
- Braun MC Welch TR Continuous venovenous hemodiafiltration in the treatment of acute hyperammonemia. American Journal of Nephrology. 1998;18:531. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources